Jason Cohen

About the Author Jason Cohen

Jason is a Smarter Analyst editor and writer, who specializes in biotech and cannabis-based pharmaceutical companies.

Piper Jaffray Pounds the Table on Canopy Growth (CGC) Stock

With Canada rolling out the red carpet for cannabis, a handful of pot stocks have emerged as potential winners in the eyes of …

Amarin (AMRN): New Survey Offers Insight Into Vascepa Market Opportunity

Amarin’s (AMRN) Vascepa is currently approved to treat around 3.8 million Americans with high triglycerides, as an adjunct to diet.

Is It Too Late to Join the OncoCyte (OCX) Stock Party? Analyst Weighs In

Investors love healthcare stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Shares of …

Should You Buy Amarin (AMRN) Stock? 4 Pros, 4 Cons

Year-to-date, Amarin (AMRN) stock is up nearly 20% due to Pfizer buyout chatter. According to rumors, the pharma giant is interested in making …

Spooked Investors Send ResMed (RMD) Stock Spiraling; Analysts Weigh In

Send ResMed (RMD) shares tanked nearly 18% today, leaving investors at odds over when it will hit a bottom. What’s causing investors to hit …

Avalon Globocare (AVCO) Stock: The Wolf of Wall Street?

Low-priced biotech stocks are often targets of pump-and-dump manipulation scams or other activity designed to make money for a select few, not you …

TherapeuticsMD (TXMD) Stock Has Triple-Digit Upside From Here, Says Analyst

TherapeuticsMD (TXMD) investors are keeping an eye on the pace of commercialization efforts for Imvexxy, Annovera, and Bijuva. That will prove critical for …

Here’s Why This Analyst Doubled His Price Target on New Age Beverages (NBEV) Stock

After seeing struggles in 2018, marijuana stocks are back in the limelight. With new legalization efforts taking place and the evolution of the …

Should You Pull the Trigger on Aphria (APHA) Stock? This Analyst Says Yes, But Be Cautious

Whether you realize it or not, the cannabis industry had an incredible year in 2018. You might not think this was the case, …

Amarin (AMRN): Management Is Flying in the Dark

A lot of Amarin (AMRN) stock bulls expected shares to fly up toward $30 following shockingly good results of the company’s Reduce-It cardiovascular …